MI
MIRA.US MIRA Pharmaceuticals, Inc. Common Stock
- Market cap
- USD 26.5M
- P/E
- -
- P/B
- 3.40x
- ROE
- -57.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is MIRA.US undervalued?
Graham numberThe Graham number of MIRA Pharmaceuticals, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
MIRA Pharmaceuticals, Inc. Common Stock fundamental analysis
No fundamental analysis for MIRA Pharmaceuticals, Inc. Common Stock yet.
MIRA Pharmaceuticals, Inc. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About MIRA Pharmaceuticals, Inc. Common Stock
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a next-generation oral NMDA receptor modulator, that has completed a Phase 1 clinical trial. It also offers oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering fr…
Full company profileMIRA Pharmaceuticals, Inc. Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
MIRA Pharmaceuticals, Inc. Common Stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | - | - | - | -8.53M | - | - | - |
| Operating Income | -67.6K | -2.15M | -7.05M | -8.53M | -8.02M | -10.5M | -4.52M |
| EBITDA | -67.6K | -2.15M | -7.05M | -8.53M | -8.02M | -10.4M | -4.61M |
| Net Income | -68.0K | -2.18M | -7.06M | -12.0M | -7.85M | -10.4M | -4.72M |
| EPS | 0.00 | -0.15 | -0.48 | -0.65 | -0.51 | -0.44 | -0.11 |
| Balance Sheet | |||||||
| Total Assets | 22.4K | 3.36M | 858K | 4.93M | 2.92M | 11.1M | 8.20M |
| Total Liabilities | 90.4K | 1.09M | 1.45M | 558K | 723K | 702K | 40.8K |
| Shareholders' Equity | -68.0K | 2.26M | -596K | 4.37M | 2.20M | 10.4M | 8.16M |
| Cash & Short-term Investments | 3.49K | 2.81M | 351K | 4.60M | 2.83M | 6.35M | 8.11M |
| Total Debt | 90.0K | 293K | 491K | 5.06K | - | - | - |
| Cash Flow | |||||||
| Operating Cash Flow | -68.0K | -1.38M | -5.60M | -4.53M | -5.56M | -4.66M | -4.81M |
| Capital Expenditure | 3.00 | 0.00 | 0.00 | 1.00 | 4.00 | 0.00 | 12.00 |
| Free Cash Flow | -68.0K | -1.38M | -5.60M | -4.53M | -5.56M | -4.66M | -4.81M |
| Ratios | |||||||
| ROE | - | -96.2% | - | -273.9% | -357.0% | -100.5% | -57.8% |
| ROA | -303.9% | -64.9% | -822.6% | -242.9% | -268.6% | -94.1% | -57.5% |
| Debt to Equity | - | 0.13x | - | 0.00x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
MIRA Pharmaceuticals, Inc. Common Stock dividends
MIRA Pharmaceuticals, Inc. Common Stock has not paid dividends in the last 6 fiscal years.
Who owns MIRA Pharmaceuticals, Inc. Common Stock
- Insiders 30.58%
- Institutions 5.86%
- Public & others 63.56%
- Shares outstanding 42.0M
- Free float 38.7M
Top funds holding MIRA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 394K | 0.94% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 218K | 0.52% | +47.04% | Sep 2026 |
| iShares Micro-Cap ETF | 92.4K | 0.22% | 0.00% | Oct 2026 |
| Fidelity Series Total Market Index | 42.0K | 0.10% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 35.9K | 0.09% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 12.6K | 0.03% | 0.00% | Aug 2026 |
| 1290 VT Micro Cap K | 8.24K | 0.02% | 0.00% | Sep 2026 |
Top institutions holding MIRA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard Capital Management, LLC | 752K | 1.79% | +8.34% | Jun 2026 |
| Cross Staff Investments Inc | 359K | 0.86% | 0.00% | Sep 2026 |
| Geode Capital Management, LLC | 304K | 0.72% | +4.47% | Jun 2026 |
| BlackRock Inc | 245K | 0.58% | +117.74% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 171K | 0.41% | +0.70% | Jun 2026 |
| CapTrust Financial Advisors | 90.6K | 0.22% | 0.00% | Jun 2026 |
| Northern Trust Corp | 67.7K | 0.16% | +0.05% | Jun 2026 |
| First American Bank/Carpentersville IL | 60.0K | 0.14% | 0.00% | Jun 2026 |
| Commonwealth Equity Services, LLC | 53.2K | 0.13% | +51.68% | Jun 2026 |
| State Street Corp | 49.1K | 0.12% | 0.00% | Jun 2026 |
| International Assets Investment Management, LLC | 35.0K | 0.08% | 0.00% | Jun 2026 |
| Fifth Third Bancorp | 20.0K | 0.05% | 0.00% | Jun 2026 |
| Citadel Advisors Llc | 18.7K | 0.04% | 0.00% | Jun 2026 |
| Susquehanna International Group, LLP | 18.6K | 0.04% | -26.17% | Jun 2026 |
| Mariner Wealth Advisors LLC | 16.5K | 0.04% | 0.00% | Jun 2026 |
| XTX Topco Ltd | 16.4K | 0.04% | -56.42% | Jun 2026 |
| HRT FINANCIAL LLC | 13.5K | 0.03% | 0.00% | Jun 2026 |
| CARY STREET PARTNERS FINANCIAL LLC | 10.0K | 0.02% | 0.00% | Jun 2026 |
| Federation des caisses Desjardins du Quebec | 8.00K | 0.02% | 0.00% | Jun 2026 |
| Advisor Group Holdings, Inc. | 2.00K | 0.00% | 0.00% | Jun 2026 |
MIRA Pharmaceuticals, Inc. Common Stock company profile
- Company name
- MIRA Pharmaceuticals, Inc. Common Stock
- Ticker
- MIRA.US
- Exchange
- USA Stocks
- Listed since
- Aug 3, 2023
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Fiscal year end
- December
- Address
- 1200 Brickell Avenue, Miami, FL, United States, 33131
- Phone
- 786 432 9792
- Website
- mirapharmaceuticals.com
About MIRA Pharmaceuticals, Inc. Common Stock
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a next-generation oral NMDA receptor modulator, that has completed a Phase 1 clinical trial. It also offers oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia; and SKNY-1, that is in preclinical stage for obesity and nicotine dependence. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is based in Miami, Florida.
MIRA Pharmaceuticals, Inc. Common Stock management
3- Mr. Erez AminovCEO & Chairman · born 1978
- Mr. Andriy Mushak CPAChief Financial Officer · born 1983
- Dr. Itzchak Angel Ph.D.Chief Scientific Advisor